• EyePoint receives C-code and pass-through payment status for Dexycu

    2 monthes ago - By Healio

    The CMS approved transitional pass-through status and reimbursement through a C-code for Dexycu, an FDA-approved treatment of postoperative inflammation after ocular surgery, EyePoint Pharmaceuticals announced.
    Dexycu , a dropless therapeutic designed to treat inflammation associated with cataract surgery, is administered as a single intraocular dose. The code, C9034, will become effective Oct. 1, according to a company press release.
    “The receipt of pass-through status and the assignment of a C-code from CMS marks another important step forward in
    Read more ...